Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment

Novel Proteasome Inhibitors to Overcome Bortezomib Resistance

(2011) Amy M. Ruschak et al.   JNCI-Journal of the National Cancer Institute

Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma

(2010) Haruhiko Nakayama et al.   CANCER

Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy

(2010) J. J. Wright   CLINICAL CANCER RESEARCH

Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells

(2010) Barbie Taylor-Harding et al.   GYNECOLOGIC ONCOLOGY

Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival

(2009) C A Barton et al.   BRITISH JOURNAL OF CANCER

Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

(2009) D. Etemadmoghadam et al.   CLINICAL CANCER RESEARCH

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

(2009) Carol Aghajanian et al.   GYNECOLOGIC ONCOLOGY

Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer

(2009) Shahab Uddin et al.   LABORATORY INVESTIGATION

Identification of Genes With Differential Expression in Chemoresistant Epithelial Ovarian Cancer Using High-Density Oligonucleotide Microarrays

(2009) Woong Ju et al.   ONCOLOGY RESEARCH

lumi: a pipeline for processing Illumina microarray

(2008) P. Du et al.   BIOINFORMATICS

Indole-3-carbinol as a chemopreventive and anti-cancer agent

(2008) Jing-Ru Weng et al.   CANCER LETTERS

Bortezomib (Velcade) Induces p27Kip1 Expression through S-Phase Kinase Protein 2 Degradation in Colorectal Cancer

(2008) S. Uddin et al.   CANCER RESEARCH

Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours

(2008) S. Cresta et al.   EUROPEAN JOURNAL OF CANCER

Targeting the c-MET signaling pathway for cancer therapy

(2008) Xiangdong Liu et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells

(2008) Madhwa H.G. Raj et al.   GYNECOLOGIC ONCOLOGY

TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance

(2008) Nathalie Wong et al.   INTERNATIONAL JOURNAL OF CANCER

Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis

(2008) Ansgar Brüning et al.   INVESTIGATIONAL NEW DRUGS

Early Events in the Pathogenesis of Epithelial Ovarian Cancer

(2008) Charles N. Landen et al.   JOURNAL OF CLINICAL ONCOLOGY

Drug development of MET inhibitors: targeting oncogene addiction and expedience

(2008) Paolo M. Comoglio et al.   NATURE REVIEWS DRUG DISCOVERY

The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing

(2008) H. H. Nguyen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer

(2007) Pedro T. Ramirez et al.   GYNECOLOGIC ONCOLOGY